$RCHA NEW AUDITOR! On Sep 18, 2017, filed an 8-K w
Post# of 103076
HypGen uses Rich's phorbol esters IP in PD indication
Aug 2017
Executive Summary
HypGen Inc. (formerly Mega Bridge Inc.) will use Rich Pharmaceuticals Inc.'s intellectual property related to 12-O-tetradecanoylphorbol-13-acetate (TPA) to develop Parkinson's disease (PD) therapeutics.
https://scrip.pharmamedtechbi.com/deals/201720373